Related news from
Wed, 06 May 2026 17:04:56 +0000	Cencora (COR) Q2 2026 Earnings Transcript Robert Mauch: Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's Fiscal 2026 Second Quarter Earnings Call. In our fiscal second quarter, we saw operating income growth in both our U.S. and International Healthcare Solutions segments and delivered adjusted diluted EPS growth of 7.5%.
Wed, 06 May 2026 16:48:33 +0000	Cencora, Inc. Q2 2026 Earnings Call Summary Moby summary of Cencora, Inc.'s Q2 2026 earnings call
Wed, 06 May 2026 15:57:00 +0000	COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.
Wed, 06 May 2026 11:45:03 +0000	Cencora (COR) Misses Q2 Earnings and Revenue Estimates Cencora (COR) delivered earnings and revenue surprises of -1.04% and -2.98%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wed, 06 May 2026 10:46:25 +0000	Cencora (NYSE:COR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings Healthcare distributor Cencora (NYSE:COR) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $78.36 billion. Its non-GAAP profit of $4.75 per share was in line with analysts’ consensus estimates.
Wed, 06 May 2026 10:30:00 +0000	Cencora Reports Fiscal 2026 Second Quarter Results CONSHOHOCKEN, Pa., May 06, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, inc
Tue, 05 May 2026 22:05:18 +0000	Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates Solventum (SOLV) delivered earnings and revenue surprises of +9.36% and +1.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tue, 05 May 2026 14:32:00 +0000	Cencora to Report Q2 Earnings: What's in Store for the Stock? COR heads into Q2 earnings with expected steady specialty-driven growth, but customer losses and pricing pressures could temper results.
Mon, 04 May 2026 15:40:04 +0000	CON vs. COR: Which Stock Is the Better Value Option? CON vs. COR: Which Stock Is the Better Value Option?
Fri, 01 May 2026 13:15:08 +0000	Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Thu, 30 Apr 2026 14:00:21 +0000	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 30 Apr 2026 04:30:00 +0000	2 Things Matter Most in Picking Winning Stocks, Says This Market Pro Adam Parker’s Trivariate Research analyzes stocks from a macro, fundamental, and quantitative perspective.
Wed, 29 Apr 2026 14:00:16 +0000	Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tue, 28 Apr 2026 21:45:03 +0000	CareDx (CDNA) Q1 Earnings and Revenues Top Estimates CareDx (CDNA) delivered earnings and revenue surprises of +209.09% and +7.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tue, 28 Apr 2026 15:55:52 +0000	William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder? William Blair launched coverage of Cardinal Health (NYSE:CAH) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside. The firm simultaneously initiated McKesson (NYSE:MCK) at Outperform, a dual launch that signals conviction in the U.S. drug-distribution oligopoly. For prudent investors, the call tightens an already constructive sell-side picture on ... William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Ste
Mon, 27 Apr 2026 17:31:00 +0000	Cardinal Health Pre-Q3 Analysis: Buy, Hold or Sell the Stock Now? CAH's Q3 results are likely to benefit from strong specialty momentum and GMPD progress, but tougher comps and tariff pressures may test upside.
Mon, 27 Apr 2026 11:02:00 +0000	CareMetx Acquires U.S.-based Patient Services and Free Goods Pharmacy Operations from Cencora, Significantly Expanding Its Patient Access Platform As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients.BETHESDA, MD, April 27, 2026 (GLOBE NEWSWIRE) -- CareMetx, the market-leading technology-enabled patient services provider, today announced the acquisition of Cencora's U.S. Hub consulting services operations previously conducted under the Lash Group and including TheraCom free goods pharmacy. The transaction substantially increases CareMetx'
Fri, 24 Apr 2026 16:28:54 +0000	Cencora, Inc. (COR) Expands Into Retina Services Business in $1.1B Deal Cencora, Inc. (NYSE:COR) is one of the stocks positioned for breakout growth. On March 24, UBS reiterated a Buy rating on Cencora, Inc. (NYSE:COR) with a $410 price target. The bullish stance is in response to the company’s announcement of the acquisition of EyeSouth’s partner’s retina business for $1.1 billion. The acquisition marks an important […]
Thu, 23 Apr 2026 23:33:23 +0000	1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing Challenges Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Thu, 23 Apr 2026 14:30:00 +0000	RIS Rx Welcomes Industry Pioneer Tom Doyle as Senior Advisor IRVINE, Calif., April 23, 2026--RIS Rx welcomes Tom Doyle as Senior Advisor, strengthening its leadership in real-time GTN Revenue Protection for pharmaceutical manufacturers.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!